GSK (GSK) Competitors

AstraZeneca (LON:AZN) and GSK (LON:GSK) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk, institutional ownership and community ranking.

Does the media prefer AZN or GSK?

In the previous week, AstraZeneca had 4 more articles in the media than GSK. MarketBeat recorded 6 mentions for AstraZeneca and 2 mentions for GSK. AstraZeneca's average media sentiment score of 0.23 beat GSK's score of -0.12 indicating that AstraZeneca is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AstraZeneca	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
GSK	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is AZN or GSK more profitable?

AstraZeneca has a net margin of 13.01% compared to GSK's net margin of 8.02%. GSK's return on equity of 18.08% beat AstraZeneca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AstraZeneca	13.01%	17.76%	7.68%
GSK	8.02%	18.08%	9.56%

Which has higher valuation and earnings, AZN or GSK?

AstraZeneca has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AstraZeneca	£66.95B	2.96	£8.71B	£364.83	28.27
GSK	£31.14B	1.76	£2.50B	£61.91	21.78

Which has more volatility and risk, AZN or GSK?

AstraZeneca has a beta of 0.17, meaning that its stock price is 83% less volatile than the S&P 500. Comparatively, GSK has a beta of 0.31, meaning that its stock price is 69% less volatile than the S&P 500.

Do analysts rate AZN or GSK?

AstraZeneca presently has a consensus price target of GBX 6,303.50, indicating a potential downside of 38.87%. GSK has a consensus price target of GBX 1,805.83, indicating a potential upside of 33.96%. Given GSK's higher possible upside, analysts clearly believe GSK is more favorable than AstraZeneca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AstraZeneca	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
GSK	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Does the MarketBeat Community believe in AZN or GSK?

AstraZeneca received 773 more outperform votes than GSK when rated by MarketBeat users. Likewise, 63.76% of users gave AstraZeneca an outperform vote while only 50.35% of users gave GSK an outperform vote.

Company	Underperform	Outperform
AstraZeneca	Outperform Votes 1863 63.76%	Underperform Votes 1059 36.24%
GSK	Outperform Votes 1090 50.35%	Underperform Votes 1075 49.65%

Is AZN or GSK a better dividend stock?

AstraZeneca pays an annual dividend of GBX 234 per share and has a dividend yield of 2.3%. GSK pays an annual dividend of GBX 60 per share and has a dividend yield of 4.5%. AstraZeneca pays out 64.1% of its earnings in the form of a dividend. GSK pays out 96.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Do institutionals & insiders have more ownership in AZN or GSK?

51.0% of AstraZeneca shares are owned by institutional investors. Comparatively, 45.3% of GSK shares are owned by institutional investors. 0.0% of AstraZeneca shares are owned by company insiders. Comparatively, 1.6% of GSK shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

AstraZeneca beats GSK on 13 of the 20 factors compared between the two stocks.